FY2026 EPS Estimate for Intuitive Surgical Raised by Analyst

Key Points

• Erste Group raised Intuitive Surgical’s FY2026 EPS estimate slightly to $8.94 from $8.93, above the analyst consensus of $8.87.
• Intuitive Surgical recently beat quarterly expectations, reporting $2.80 EPS versus $2.48 expected and $2.89 billion in revenue, up 18.4% year over year.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $498.83, although valuation and some recent price-target reductions remain potential risks.

Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) - Research analysts at Erste Group Bank upped their FY2026 earnings per share estimates for shares of Intuitive Surgical in a research note issued to investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now forecasts that the medical equipment provider will post earnings of $8.94 per share for the year, up from their prior estimate of $8.93. The consensus estimate for Intuitive Surgical's current full-year earnings is $8.87 per share.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company had revenue of $2.89 billion during the quarter, compared to analysts' expectations of $2.83 billion. During the same period in the prior year, the business posted $1.81 EPS. Intuitive Surgical's quarterly revenue was up 18.4% compared to the same quarter last year.

A number of other analysts have also weighed in on the company. BNP Paribas Exane raised Intuitive Surgical to an "outperform" rating in a research note on Tuesday, July 28th. Barclays upgraded shares of Intuitive Surgical to a "strong-buy" rating in a report on Wednesday, October 7th. Royal Bank Of Canada decreased their target price on shares of Intuitive Surgical from $650.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. KeyCorp reiterated an "overweight" rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Finally, TD Cowen lowered shares of Intuitive Surgical from a "buy" rating to a "hold" rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $498.83.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $422.06 on Wednesday. The business's 50 day simple moving average is $388.49 and its two-hundred day simple moving average is $410.14. The stock has a market capitalization of $149.11 billion, a P/E ratio of 48.35, a price-to-earnings-growth ratio of 3.23 and a beta of 1.46. Intuitive Surgical has a one year low of $328.57 and a one year high of $603.88.

Hedge Funds Weigh In On Intuitive Surgical

Several hedge funds have recently made changes to their positions in ISRG. Invesco Ltd. grew its position in shares of Intuitive Surgical by 17.4% during the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider's stock valued at $2,338,350,000 after acquiring an additional 611,268 shares during the period. Bank of America Corp DE increased its stake in shares of Intuitive Surgical by 3.3% in the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider's stock worth $1,667,388,000 after purchasing an additional 116,292 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Intuitive Surgical in the 2nd quarter worth $1,335,753,000. Amundi raised its holdings in Intuitive Surgical by 8.6% in the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider's stock worth $1,119,448,000 after purchasing an additional 193,096 shares during the period. Finally, J. Stern & Co. LLP raised its holdings in Intuitive Surgical by 18,504.6% in the 4th quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider's stock worth $1,204,788,000 after purchasing an additional 2,115,814 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, VP Fredrik Widman sold 1,089 shares of the company's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total transaction of $407,765.16. Following the completion of the transaction, the vice president owned 1,026 shares of the company's stock, valued at $384,175.44. This represents a 51.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total value of $28,918.89. Following the completion of the sale, the executive vice president owned 881 shares of the company's stock, valued at approximately $330,877.17. This trade represents a 8.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,370 shares of company stock valued at $4,891,989 over the last ninety days. Corporate insiders own 0.60% of the company's stock.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical is expanding beyond traditional surgery by submitting a next-generation robotic endoscope to the FDA for gastrointestinal procedures. Approval could open a significant new growth market and broaden the company’s recurring-procedure opportunity. ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters
• Positive Sentiment: Zacks upgraded ISRG to Rank #2, or “Buy,” citing improving earnings prospects. The upgrade may support sentiment ahead of the company’s quarterly report. Intuitive Surgical Upgraded to Buy
• Positive Sentiment: UBS reiterated a Buy rating and maintained a $500 price target, pointing to Intuitive Surgical’s long-term robotic-surgery growth runway. Leerink Partners also maintained its Buy recommendation. Intuitive Surgical Buy Rating Reiterated
• Positive Sentiment: Erste Group raised its fiscal 2027 EPS estimate slightly to $10.09 from $10.06, above the current-year consensus estimate of $8.87, reinforcing expectations for continued earnings growth.
• Neutral Sentiment: Intuitive Surgical is being highlighted as a sales-growth stock ahead of third-quarter earnings. Its prior quarter included 18.4% year-over-year revenue growth and an earnings beat, but investors are likely waiting for updated results and guidance. 3 Sales Growth Stocks to Buy as Q3 Earnings Get Underway
• Negative Sentiment: BTIG lowered its price target to $454 from $469 while keeping a Buy rating. Although the revised target still implies upside, the cut may weigh on near-term sentiment and signals more cautious expectations.
• Negative Sentiment: Valuation remains a potential pressure point: Intuitive Surgical trades at a substantially higher forward earnings multiple than Abbott Laboratories, leaving the stock sensitive to any earnings miss, slower procedure growth, or conservative guidance. Abbott Laboratories vs. Intuitive Surgical

About Intuitive Surgical

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company's products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.